Directory | Public | QUEST3+ System

Increase size

Reset to Default

Decrease size

PENGSTRUKTURAN SEMULA BAHAGIAN REGULATORI FARMASI NEGARA KEMENTERIAN KESIHATAN MALAYSIA

Untuk makluman YBhg. Datuk / Dato’ / Datin / Dr. / Tuan / Puan, Bahagian Regulatori Farmasi Negara (NPRA), Kementerian Kesihatan Malaysia (KKM) akan melaksanakan proses pengstrukturan semula pada bulan Disember 2019. Struktur baru NPRA yang akan berkuatkuasa mulai 02 Disember 2019 tersebut adalah seperti di Lampiran A

Sehubungan itu, dimaklumkan bahawa proses ini akan turut melibatkan pergerakan dalaman sebilangan anggota NPRA berdasarkan lokasi baharu setiap pusat / seksyen di dalam premis NPRA. Oleh itu, mengambil kira pergerakan dalaman serta perubahan nombor telefon yang akan berlaku dalam tempoh ini, komunikasi melalui saluran emel adalah amat digalakkan untuk memastikan kelancaran perkhidmatan.

RESTRUCTURING OF THE NATIONAL PHARMACEUTICAL REGULATORY AGENCY MINISTRY OF HEALTH MALAYSIA

With reference to the subject matter as above, kindly be informed that the National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health (MOH) Malaysia will be undergoing a restructuring exercise. This restructuring exercise is estimated to take place beginning December 2019. The new structure which will be effective as of 2^nd December 2019 is attached herewith for your kind reference (refer Attachment A).

Kindly note that this restructuring exercise will involve the relocation of certain NPRA officers in accordance to the new sections / centres within the premise of NPRA. As communication via telephone may be a challenge due to this relocation process, we strongly encourage communications to be done via e-mail during this period to ensure the continuity of services provided.

QUEST3+ System Registration ProcessHow to register as a user in QUEST3+ system?

Registration for the QUEST 3+ System is simple,
and no regulatory consultant/agent* services should be required

Quality Control Centre has maintained theMS ISO/IEC 17025:2005

accreditation certificate by Jabatan Standards Malaysia on 30 August 2018.
Accreditation will be valid until 30 November 2020

SCAM TELEPHONE CALLSNOTICE

Recently, the NPRA has received reports from the public regarding scam telephone calls that
were made by individuals who claimed to be NPRA officers.

More Information

NPRA mission is to safeguard the nation’s health through scientific excellence in the regulatory control of medicinal products and cosmetics.

REGISTER YOUR PRODUCTS NOW

Consumers

ConSERF, AEFI Reporting, RiMUP, Product Cancellation & etc

Health Professionals

Safety Alert, Reporting ADR, MADRAC, Product Complaints, Publications

Industries

Product Registration, QUEST3+ System, Guideline Central, Application Forms, FAQs.

PRODUCT SEARCH

Check product status including pharmaceutical, natural & cosmetic products

REPORTING OF SIDE EFFECTS TO MEDICINES OR VACCINES

To report a suspected side effect or adverse drug reaction (ADR) to any medicine or vaccine

Report ADR as Consumers

Report ADR as Health Care Professional

ANNOUNCEMENTS
RECENT UPDATES
PRESS RELEASE
DIRECTIVES & CIRCULARS
SAFETY ALERTS
CALENDAR ACTIVITIES

13Jan

MOPI Training - International Good Manufacturing Training Program 2020

16Dec

Change in Administrative Procedure for Section S Revision for Registered Products (Non Anti-Infectives) with the Expiration of Registration Starting 1 January 2020

05Dec

MAKLUMAT TERKINI STATUS PRODUK RANITIDINE BERKAITAN IMPURITI N-NITROSODIMETHYLAMINE (NDMA) [Kemaskini:05/12/2019]

03Dec

Update of Guidance Notes for API Information for Product Registration - Version 4.0 (December 2019)

26Nov

HSA-NPRA Generic Medicines Work Sharing Initiative

26Nov

Soalan-soalan Lazim (FAQ): Impuriti NDMA di dalam Produk Ranitidine

View All Announcements

Philippines FDA included in list of ASEAN Listed Inspection Services
published on 2020-01-21

New safety measure for sodium valproate: (i) Risk of congenital malformation in neonates and neurodevelopmental problems in children exposed to sodium valproate during pregnancy; (ii) Additional educational material for healthcare professionals and patients/caretakers
published on 2020-01-20

Additional Indications Approved
published on 2020-01-17

New Products Approved
published on 2020-01-17

MOPI Training - International Good Manufacturing Training Program 2020
published on 2020-01-13

More Recent Updates

24Dec

KENYATAAN AKHBAR KPK 24 Disember 2019-Produk-Produk Kosmetik Yang Dikesan Mengandungi Racun Berjadual

05Dec

Kenyataan Akhbar KPK 5 Disember 2019 – ISU PANGGIL BALIK TIGA PRODUK METFORMIN DARIPADA PASARAN SINGAPURA

31Oct

MAKLUMAT TERKINI BERKAITAN PENILAIAN SEMULA PRODUK BERDAFTAR YANG MENGANDUNGI BAHAN AKTIF RANITIDINE BERIKUTAN PENGESANAN IMPURITI N-NITROSODIMETHYLANIBE (NDMA)

View All Press Release

09Jan

Direktif untuk semua produk yang mengandungi sulfasalazine: Pengemaskinian sisip bungkusan dan risalah maklumat ubat untuk pengguna (RiMUP) dengan maklumat keselamatan berkaitan risiko gangguan terhadap ujian makmal yang menggunakan reaksi dihydronicotinamide-adenine dinucleotide/ dihydronicotinamide-adenine dinucleotide phosphate (NADH/NADPH)

09Jan

Direktif untuk semua produk yang mengandungi sodium valproate: pengukuhan maklumat keselamatan pada label, sisip bungkusan dan risalah maklumat ubat untuk pengguna (RiMUP) berkaitan risiko kecacatan kongenital dan masalah perkembangan dalam kalangan bayi dan kanak-kanak yang terdedah kepada penggunaan sodium valproate semasa dalam kandungan dan penyediaan bahan-bahan pengajaran

04Dec

Second Source and Replacement Products

View All Directives & Circulars

26Nov

Retinoids: Updated measures for pregnancy prevention during retinoids use

26Nov

FEBURIC® (febuxostat): Increased risk of cardiovascular death and all-cause mortality in patients treated with febuxostat in the CARES study

30Oct

Smecta® (dioctahedral smectite): Not recommended for use in children aged below 2 years and pregnant or breastfeeding women

View All Safety Alerts

02 Dec 2019;
08:00AM - 05:00PM
Career Development Course : Effective Communication at the Workplace

03 Dec 2019;
08:00AM - 05:00PM
Career Development Course : Reasoning and Decision Making

04 Dec 2019;
08:00AM - 05:00PM
Career Development Course : Managing Change – assessing the resistance and readiness

17 Feb 2020;
08:00AM - 05:00PM
GMP – What You Need to Know

03 Mar 2020;
08:00AM - 05:00PM
Risk Management – Quality System and Process

View Full Calendar

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.

Email: npra@npra.gov.my
Phone: +603-7883 5400
Fax: +603-7956 2924, +603-7956 7075

More Links

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

Last Modified: Wednesday 22 January 2020, 16:07:42.